Cyprotex
Anu Marahatta is an accomplished associate principal scientist at Cyprotex, specializing in in vivo DMPK studies and the design and execution of ADME/PK studies since October 2020. Previously, Anu served as a research associate at Cincinnati Children's Hospital Medical Center where methods for quantifying hydroxyurea in biological matrices were developed, along with pharmacokinetic studies in various mouse models. As a PhD student at Chonbuk National University, Anu led multiple scientific projects culminating in publications and conference presentations. Early career experiences include roles as a quality control officer at Omnica Laboratory and Pharmaco Private Ltd., and a production officer at Quest Pharmaceuticals. Anu holds a Ph.D. from Jeonbuk National University and a Bachelor of Pharmacy from Kathmandu University.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology